Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
In the week ended Dec. 19, that message was clear. ARK Investment Management leaned harder into AI-led biotechnology and crypto, while paring back exposure to consumer tech and electric-vehicle heavyweights. At the center of that shift sat Recursion Pharmaceuticals (RXRX). ARK snapped up more than 2.8 million RXRX shares, worth about $13.4 million, spread across ARK Genomic Revolution ETF (ARKG) and flagship ARK Innovation ETF (ARKK). The additions lifted Recursion to the No. 27 holding in ARKK and a top-10 position in ARKG. The Utah-based biotech is betting on artificial intelligence (AI) to radically shorten drug discovery timelines, a thesis that neatly mirrors Wood's long-held view of innovation reshaping healthcare. 2 Dividend Kings Quietly Beating the Market This Year Apple Just Released a New AI Model. Should You Buy AAPL Stock Here? Broadcom (AVGO) Stock Options Are Signaling Pensiveness. Here's Why the Fear Might Be Unwarranted. Stop Missing Market Moves: Get the FR
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]Yahoo! Finance
- Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.MarketBeat
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/23/25 - Form SCHEDULE
- 12/22/25 - Form 144
- 12/19/25 - Form 4
- RXRX's page on the SEC website